Chronic Rapamycin Treatment Causes Glucose Intolerance and Hyperlipidemia by Upregulating Hepatic Gluconeogenesis and Impairing Lipid Deposition in Adipose Tissue
Article Information
vol. 59 no. 6 1338-1348
PubMed
Published By
Print ISSN
Online ISSN
History
- Received September 4, 2009
- Accepted February 23, 2010
- Published in print May 27, 2010.
- Published online ahead of print March 18, 2010.
Article Versions
- Previous version (March 18, 2010 - 07:16).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2010 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
Author Information
- Vanessa P. Houde1,
- Sophie Brûlé1,
- William T. Festuccia2,
- Pierre-Gilles Blanchard2,
- Kerstin Bellmann1,
- Yves Deshaies2 and
- André Marette1
- 1Department of Medicine, Faculty of Medicine, Cardiology Axis of the Quebec Heart and Lung Institute, and the Metabolism, Vascular and Renal Health Axis, Laval University Hospital Research Center, Laval University, Quebec, Canada; and
- 2Department of Medicine, Faculty of Medicine, Obesity-Metabolism Axis of the Quebec Heart and Lung Institute, Laval University, Quebec, Canada.
- Corresponding author: André Marette, andre.marette{at}crchul.ulaval.ca.
-
V.P.H. and S.B. contributed equally to this study.
Statistics from Altmetric.com
Article usage
In this Issue
June 2010, 59(6)
Chronic Rapamycin Treatment Causes Glucose Intolerance and Hyperlipidemia by Upregulating Hepatic Gluconeogenesis and Impairing Lipid Deposition in Adipose Tissue
